Frequencies of CYP2C19 and CYP2D6 gene variants in a German inpatient sample with mood and anxiety disorders

References

• Beunk L, Nijenhuis M, Soree B, de Boer-Veger NJ, Buunk AM, Guchelaar HJ, Houwink EJF, Risselada A, Rongen G, van Schaik RHN, et al. 2023. Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics. Eur J Hum Genet. 32(3):278–285. doi: 10.1038/s41431-023-01347-3.
   PubMed Web of Science ®Google Scholar
• Bousman CA, Bengesser SA, Aitchison KJ, Amare AT, Aschauer H, Baune BT, Asl BB, Bishop JR, Burmeister M, Chaumette B, et al. 2021. Review and consensus on pharmacogenomic testing in psychiatry. Pharmacopsychiatry. 54(1):5–17. doi: 10.1055/a-1288-1061.
   PubMedGoogle Scholar
• Bousman C, Maruf AA, Müller DJ. 2019. Towards the integration of pharmacogenetics in psychiatry: a minimum, evidence-based genetic testing panel. Curr Opin Psychiatry. 32(1):7–15. doi: 10.1097/YCO.0000000000000465.
   PubMed Web of Science ®Google Scholar
• Bousman CA, Stevenson JM, Ramsey LB, Sangkuhl K, Hicks JK, Strawn JR, Singh AB, Ruaño G, Mueller DJ, Tsermpini EE, et al. 2023. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants. Clin Pharmacol Ther. 114(1):51–68. doi: 10.1002/cpt.2903.
   PubMed Web of Science ®Google Scholar
• Bousman CA, Wu P, Aitchison KJ, Cheng T. 2021. Sequence2Script: a web-based tool for translation of pharmacogenetic data into evidence-based prescribing recommendations. Front Pharmacol. 12:636650. doi: 10.3389/fphar.2021.636650.
   PubMed Web of Science ®Google Scholar
• Bousman CA, Zierhut H, Müller DJ. 2019. Navigating the labyrinth of pharmacogenetic testing: a guide to test selection. Clin Pharmacol Ther. 106(2):309–312. doi: 10.1002/cpt.1432.
   PubMed Web of Science ®Google Scholar
• Brown JT, Bishop JR, Sangkuhl K, Nurmi EL, Mueller DJ, Dinh JC, Gaedigk A, Klein TE, Caudle KE, McCracken JT, et al. 2019. Clinical pharmacogenetics implementation consortium guideline for cytochrome P450 (CYP)2D6 genotype and atomoxetine therapy. Clin Pharmacol Ther. 106(1):94–102. eng. doi: 10.1002/cpt.1409.
   PubMed Web of Science ®Google Scholar
• Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, et al. 2018. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 391(10128):1357–1366. doi: 10.1016/S0140-6736(17)32802-7.
   PubMed Web of Science ®Google Scholar
• CPIC. 2021. CPIC - Clinical Pharmacogenetics Implementation Consortium. [accessed 2022 March 8]. https://cpicpgx.org/.
   Google Scholar
• CPIC. 2023a. CYP2C19 CPIC guidelines. Clinical Pharmacogenetics Implementation Consortium; [accessed 2023 April 27]. https://cpicpgx.org/gene/cyp2c19/.
   Google Scholar
• CPIC. 2023b. CYP2D6 CPIC guidelines. Clinical Pharmacogenetics Implementation Consortium; [accessed 2023 April 27]. https://cpicpgx.org/gene/cyp2d6/.
   Google Scholar
• Crews KR, Monte AA, Huddart R, Caudle KE, Kharasch ED, Gaedigk A, Dunnenberger HM, Leeder JS, Callaghan JT, Samer CF, et al. 2021. Clinical pharmacogenetics implementation consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy. Clin Pharmacol Ther. 110(4):888–896. doi: 10.1002/cpt.2149.
   PubMed Web of Science ®Google Scholar
• First MB, Gibbon M. 2004. The structured clinical interview for DSM-IV axis I disorders (SCID-I) and the structured clinical interview for DSM-IV axis II disorders (SCID-II). Comprehensive handbook of psychological assessment, vol 2: personality assessment. Hoboken, NJ, US: John Wiley & Sons, Inc.; p. 134–143.
   Google Scholar
• Gendiagnostik-Kommission. 2013. Richtlinie der Gendiagnostik-Kommission (GEKO) für die anforderungen an die qualitätssicherung genetischer analysen zu medizinischen zwecken gemäß § 23 abs. 2 nr. 4 GenDG. Bundesgesundheitsblatt. 56:163–168.
   Google Scholar
• Gendiagnostik-Kommission. 2017. Richtlinie der Gendiagnostik-Kommission (GEKO) für die beurteilung genetischer eigenschaften hinsichtlich ihrer bedeutung für die wirkung eines arzneimittels bei einer behandlung gemäß §23 abs. 2 nr. 1b GenDG. Bundesgesundheitsblatt. 60:472–475.
   Google Scholar
• Gu Z, Gu L, Eils R, Schlesner M, Brors B. 2014. Circlize implements and enhances circular visualization in R. Bioinformatics. 30(19):2811–2812. doi: 10.1093/bioinformatics/btu393.
   PubMed Web of Science ®Google Scholar
• Hahn M, Müller DJ, Roll SC. 2021. Frequencies of genetic polymorphisms of clinically relevant gene-drug pairs in a german psychiatric inpatient population. Pharmacopsychiatry. 54(2):81–89. doi: 10.1055/a-1312-7175.
   PubMedGoogle Scholar
• Hicks JK, Bishop JR, Sangkuhl K, Müller DJ, Ji Y, Leckband SG, Leeder JS, Graham RL, Chiulli DL, Ll A, et al. 2015. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 98(2):127–134. doi: 10.1002/cpt.147.
   PubMed Web of Science ®Google Scholar
• Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, Müller DJ, Shimoda K, Bishop JR, Kharasch ED, Skaar TC, Gaedigk A, et al. 2017. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 102(1):37–44. doi: 10.1002/cpt.597.
   PubMed Web of Science ®Google Scholar
• Hiemke C, Haen E, Eckermann G, Dobmeier M, Singer M, Silva M, Wenzel-Seifert K, Nagel-Hiemke M. 2024. PSIAC. Springer-Verlag GmbH, Heidelberg; [accessed 2019 March 18]. https://www.psiac.de/.
   Google Scholar
• INSTAND. 2020. INSTAND Gesellschaft zur Förderung der Qualitätssicherung in medizinischen Laboratorien e. V. [accessed 2020 Feb 10]. https://www.instand-ev.de/ueber-instand-ev/instand-ev.html.
   Google Scholar
• Li B, Sangkuhl K, Whaley R, Woon M, Keat K, Whirl-Carrillo M, Ritchie MD, Klein TE. 2023. Frequencies of pharmacogenomic alleles across biogeographic groups in a large-scale biobank. Am J Hum Genet. 110(10):1628–1647. doi: 10.1016/j.ajhg.2023.09.001.
   PubMed Web of Science ®Google Scholar
• Lunenburg C, Thirstrup JP, Bybjerg-Grauholm J, Bækvad-Hansen M, Hougaard DM, Nordentoft M, Werge T, Børglum AD, Mors O, Mortensen PB, et al. 2021. Pharmacogenetic genotype and phenotype frequencies in a large danish population-based case-cohort sample. Transl Psychiatry. 11(1):294. doi: 10.1038/s41398-021-01417-4.
   PubMed Web of Science ®Google Scholar
• Malhi GS, Mann JJ. 2018. Depression. Lancet. 392(10161):2299–2312. doi: 10.1016/S0140-6736(18)31948-2.
   PubMed Web of Science ®Google Scholar
• Menke A. 2018. Precision pharmacotherapy: psychiatry’s future direction in preventing, diagnosing, and treating mental disorders. Pharmgenomics Pers Med. 11:211–222. doi: 10.2147/PGPM.S146110.
   PubMed Web of Science ®Google Scholar
• Menke A, Weber H, Deckert J. 2020. Roadmap for routine pharmacogenetic testing in a psychiatric university hospital. Pharmacopsychiatry. 53(4):179–183. doi: 10.1055/a-0914-3234.
   PubMedGoogle Scholar
• Mishra S, Swain TR, Mohanty M. 2013. Adverse drug reaction monitoring of antidepressants in the psychiatry outpatients department of a tertiary care teaching hospital. J Clin Diagn Res. 7(6):1131–1134.
   PubMedGoogle Scholar
• Mostafa S, Polasek TM, Sheffield LJ, Huppert D, Kirkpatrick CMJ. 2021. Quantifying the impact of phenoconversion on medications with actionable pharmacogenomic guideline recommendations in an acute aged persons mental health setting. Front Psychiatry. 12:724170. doi: 10.3389/fpsyt.2021.724170.
   PubMed Web of Science ®Google Scholar
• Murphy LE, Fonseka TM, Bousman CA, Müller DJ. 2022. Gene-drug pairings for antidepressants and antipsychotics: level of evidence and clinical application. Mol Psychiatry. 27(1):593–605. doi: 10.1038/s41380-021-01340-6.
   PubMed Web of Science ®Google Scholar
• PharmGKB. 2023a. CYP2C19 pathways. PharmGKB. [accessed 2023 April 27]. https://www.pharmgkb.org/gene/PA124/pathway.
   Google Scholar
• PharmGKB. 2023b. CYP2D6 pathways. PharmGKB. [accessed 2023 April 27]. https://www.pharmgkb.org/gene/PA128/pathway.
   Google Scholar
• PharmGKB. 2023c. Gene-specific information tables for CYP2C19. PharmGKB. [accessed 2023 April 13]. https://www.pharmgkb.org/page/cyp2c19RefMaterials.
   Google Scholar
• PharmGKB. 2023d. Gene-specific information tables for CYP2D6. PharmGKB. [accessed 2023 April 13]. https://www.pharmgkb.org/page/cyp2d6RefMaterials.
   Google Scholar
• RCoreTeam. 2021. R: A language and environment for statistical computing. https://www.R-project.org. R Foundation for Statistical Computing, Vienna, Austria.
   Google Scholar
• Relling MV, Klein TE. 2011. CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther. 89(3):464–467. doi: 10.1038/clpt.2010.279.
   PubMed Web of Science ®Google Scholar
• Relling MV, Klein TE, Gammal RS, Whirl-Carrillo M, Hoffman JM, Caudle KE. 2020. The clinical pharmacogenetics implementation consortium: 10 years later. Clin Pharmacol Ther. 107(1):171–175. doi: 10.1002/cpt.1651.
   PubMed Web of Science ®Google Scholar
• Scherf-Clavel M, Frantz A, Eckert A, Weber H, Unterecker S, Deckert J, Reif A, Hahn M. 2023. Effect of CYP2D6 pharmacogenetic phenotype and phenoconversion on serum concentrations of antidepressants and antipsychotics: a retrospective cohort study. Int J Clin Pharm. 45(5):1107–1117. doi: 10.1007/s11096-023-01588-8.
   PubMed Web of Science ®Google Scholar
• Scherf-Clavel M, Weber H, Wurst C, Stonawski S, Hommers L, Unterecker S, Wolf C, Domschke K, Rost N, Brückl T, et al. 2022. Effects of pharmacokinetic gene variation on therapeutic drug levels and antidepressant treatment response. Pharmacopsychiatry. 55(5):246–254. doi: 10.1055/a-1872-0613.
   PubMedGoogle Scholar
• Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GA, van Schaik RH, Schalekamp T, Touw DJ, et al. 2011. Pharmacogenetics: from bench to byte–an update of guidelines. Clin Pharmacol Ther. 89(5):662–673. doi: 10.1038/clpt.2011.34.
   PubMed Web of Science ®Google Scholar
• Swen JJ, Wilting I, de Goede AL, Grandia L, Mulder H, Touw DJ, de Boer A, Conemans JM, Egberts TC, Klungel OH, et al. 2008. Pharmacogenetics: from bench to byte. Clin Pharmacol Ther. 83(5):781–787. doi: 10.1038/sj.clpt.6100507.
   PubMed Web of Science ®Google Scholar
• ViennaLab Diagnostics GmbH. 2021. CYP2D6 RealFast CNV assay. ViennaLab Diagnostics GmbH.
   Google Scholar
• Whirl-Carrillo M, Huddart R, Gong L, Sangkuhl K, Thorn CF, Whaley R, Klein TE. 2021. An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 110(3):563–572. doi: 10.1002/cpt.2350.
   PubMed Web of Science ®Google Scholar
• Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, Altman RB, Klein TE. 2012. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 92(4):414–417. doi: 10.1038/clpt.2012.96.
   PubMed Web of Science ®Google Scholar
• WHO. 2023. Mental disorders. WHO Web site; [updated 08 June 2022; accessed 2023 April 20]. https://www.who.int/news-room/fact-sheets/detail/mental-disorders.
   Google Scholar